Skip to main content
. 2023 Jun 28;299(8):104981. doi: 10.1016/j.jbc.2023.104981

Figure 4.

Figure 4

High-affinity CD8 variants enhance the functionality of primary CD4+T cells transduced with cancer-targeting TCRs.A–D, primary CD4+ T cells expressing CD8αβ containing either wild-type (WT) CD8α (red) or mutated forms of CD8α, namely S53G (teal) or S53N (purple), alongside the 1E9 TCR were cocultured with a panel of cell lines lacking or expressing CD20. The panels show representative IFN-γ (A) or IL-2 production (C) from a single donor (triplicate measurements) or IFN-γ (B) or IL-2 production (D) from each of three donors. E and F, primary CD4+ T cells expressing CD8αβ containing either wild-type (WT) CD8α (red) or mutated forms of CD8α, namely S53G (teal) or S53N (purple), alongside the KL14 TCR were cocultured with a panel of cell lines lacking or expressing CTAG1. The panels show representative IFN-γ production (E) from a single donor (duplicate measurements) or IFN-γ production (F) from each of two donors. Data are shown as mean ± SD (A–F). Significance was determined using a one-way ANOVA with Dunnett’s post hoc test to compare each variant versus wild-type CD8. TCM, T cell medium.